Outcomes of berberina in dyslipidemia: a systematic review

  • Iraíldo Francico Soares Universidade Federal do Piauí (UFPI). Programa de Pós-Graduação em Alimentos e Nutrição (PPGAN). Teresina, Piauí, Brasil.
  • Amanda Suellenn da Silva Santos Oliveira Universidade Federal do Piauí (UFPI). Programa de Pós-Graduação em Alimentos e Nutrição (PPGAN). Teresina, Piauí, Brasil.
  • Joyce Lopes Macedo Universidade Federal do Piauí (UFPI). Programa de Pós-Graduação em Alimentos e Nutrição (PPGAN). Teresina, Piauí, Brasil.
  • Michele Alves de Lima Universidade Federal do Piauí (UFPI). Programa de Pós-Graduação em Alimentos e Nutrição (PPGAN). Teresina, Piauí, Brasil.
  • Robson Alves da Silva Instituto Federal de Educação, Ciência e Tecnologia do Piauí (IFPI). Teresina, Piauí, Brasil.
Keywords: Berberine, Lipid levels, Metabolism

Abstract

The aim of this systematic review is to demonstrate the results of published studies on the outcomes of berberine in dyslipidemia. Scientific articles published without time frame in the scientific databases PubMed, Scopus and EMBASE were investigated. The search was performed using the following descriptors from the Medical Subject Headings (MeSH), using Boolean operators: “Berberine†OR “Berberine Alkaloids†AND “Dyslipidemias†AND “Clinical Trialâ€. The PICOS strategy (population, intervention, comparator, performance and type of study) defined the guiding question. The Cochrane Collaboration Tool was used to assess the risk of bias of the studies included in this review. The work followed PRISMA standards for its structuring. Among the articles that met the inclusion criteria, 05 most relevant studies were selected to compose this review. The results of the studies showed beneficial effects of berberine in decreasing VLDL-C, LDL-C, total cholesterol (TC) variations and increasing HDL-C levels. The role of berberine in decreasing lipid levels acts by increasing the expression of the hepatic LDL-associated cholesterol receptor (LDLR), acting in the regulation of the extracellular kinase (ERK) signal and also by increasing the transitional activity of the LDL promoter -R via the c-Jun transcription factor (JNK) kinase pathway. The results of this systematic review provide evidence of the benefits of berberine supplementation on dyslipidemias. However, new studies must be carried out to standardize the dose, time of ingestion and possible toxicity, so that its indication and supplementation reach safe levels.

References

-Cicero, A.F.; Rovati, L.C.; Setnikar, I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Drug Research. Vol. 57. Num. 1. 2007. p. 26-30.

-Derosa, G; D’Angelo, A.; Boaventura, A.; Biachini, L.; Romano, D.; Maffioli, P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opinion on Biological Therapy. Vol. 13. Num. 4. 2013. p. 475-482.

-Di Pierro, F. Berberina. Topics on Biopharmaceutical Phytotherapy [in Italian], CEC Editore. 2016.

-Faludi, A.A.; Izar, M.C.O.; Saraiva, J.F.K.; Chacra, A.P.M.; Bianco, H.T. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose. Arquivos Brasileiros de Cardiologia. Vol. 109. Num. 2. 2017.

-Ferrari, F.; Stein, R.; Motta, M.T.; Moriguchi, E.H. Inibidores de PCSK9: Importância Clínica, Mecanismos Moleculares, e Segurança na Prática Clínica. Arquivos Brasileiros de Cardiologia. Vol. 112. Num. 4. 2019. p. 453-460.

-Gosh, N.; Mandal, S. C.; Mandal, V.; Konishi, T. Natural Products and Drug Discovery. Elsevier. 2018.

-Gu, Y.; Zhang, Y.; Shi, X.; Li, X.; Hong, J.; Chen, J.; Gu, W.; Xu, G.; Ning, G. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. Vol. 81. Num. 3. 2010. p. 766-772.

-Jia, Y.J.; Xu, R.X.; Sun, J.; Tang, J.; Li, J. Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. Journal of Translational Medicine. Vol. 12. Num. 1. 2014. p. 103-114.

-Kalmarzi, R.N.; Naleini, S.M.; Ashatary-Larky, D.; Peluso, I.; JouybariL. Anti-Inflammatory and Immunomodulatory Effects of Barberry (Berberis vulgaris) and Its Main Compounds. Oxid Med Cell Longe. Vol. 2019. Num. 10. 2019. p. 1-11.

-Kong, W.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Li, C.; Wang, Y.; Wang, Z.; Si, S.; Pan, H.; Wang, S.; Wu, J.; Wang, Y.; Li, Z.; Jiang, J.D. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Medicine. Vol. 10. Num. 12. 2004. p. 1344-1351.

-León-Martínez, J.M.; Abundis, E.M.; Ortiz, M.G.; Rubio, K.G.P. Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. Journal of Medicinal Food. Vol. 24. Num. 2. 2021. p. 111-115.

-Li, H. Dong, B.; Park, S.W.; Lee, S.H.; Chen, W.; Liu, J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. Journal of Biological Chemistry. Vol. 284. Num. 42. 2009. p. 28885-28895.

-Opoku, S.; Gan, W.; Fu, W.; Chen, D.; Yobo, E.A.; Trofimovitch, D.; Yue, W.; Yan, F.; Wang, Z.; Lu, Z. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. Vol. 19. Num. 1. 2019. p. 1500-1512.

-Patti, A. M. Natural approaches in metabolic syndrome management. Archives of Medical Science. Vol. 14. Num. 2. 2018. p. 422-441.

-Pulipati, V.P.; Davidson, M.H. Recent advances and emerging therapies in management of dyslipidemias. Trends in Cardiovascular Medicine. Vol. 20. Num. 2, 2020. p. 1050-1058.

-Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Journal of Nutrition. Vol. Num. 16. 2017. p. 14-23.

-Siri-Tarino, P.W.; Sun, Q.; Hu, F.B.; Krauss, R.M. Saturated fat, carbohydrate, and cardiovascular disease. The American Journal of Clinical Nutrition. Vol. 35. Num. 3. 2015. p. 502-509.

-Trautwein, E.A.; Mckay, S. The Role of Specific Components of a Plant-Based Diet in Management of Dyslipidemia and the Impact on Cardiovascular Risk. Nutrients. Vol. 12. Num. 9. 2020. p. 255-267.

-Yang, J.; Yin, J.; Gao, H.; Xu, L.; Lu, W.; Li, M. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med. Vol. 12, Num. 8. 2012. p. 363-375.

-Yin, J.; Xing, H.; Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. Vol. 57. Num. 5. 2008. p. 712-717.

-Zhang, Y.; Li, X.; Zou, D.; Liu, W.; Yang, J.; Zhu, N.; Hou, L.; Wang, M.; Hong, J.; Hu, P.; Ren, G.; Ning, G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. The Journal of Clinical Endocrinology and Metabolism. Vol. 93. Num. 7. 2008. p. 2559-2565.

Published
2022-07-07
How to Cite
Soares, I. F., Oliveira, A. S. da S. S., Macedo , J. L., Lima, M. A. de, & Silva, R. A. da. (2022). Outcomes of berberina in dyslipidemia: a systematic review. Brazilian Journal of Obesity, Nutrition and Weight Loss, 15(96), 822-829. Retrieved from https://www.rbone.com.br/index.php/rbone/article/view/1824
Issue
Vol. 15 No. 96 (2021)
Section
Scientific Articles - Original

Copyright (c) 2022 Iraíldo Francico Soares, Amanda Suellenn da Silva Santos Oliveira, Joyce Lopes Macedo , Michele Alves de Lima, Robson Alves da Silva

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • Authors retain the copyright and grant the journal the right of first publication, with work simultaneously licensed under the Creative Commons Attribution License BY-NC which allows the sharing of the work with acknowledgment of the authorship of the work and initial publication in this journal.
  • Authors are authorized to enter into additional contracts separately for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or book chapter), with acknowledgment of authorship and initial publication in this journal.
  • Authors are allowed and encouraged to post and distribute their work online (eg, in institutional repositories or on their personal page) at any point before or during the editorial process, as this can bring about productive change as well as increase impact and impact. citation of published work (See The Effect of Free Access).